Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
2008
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
2008 Standout
Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy
2010
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
2008
Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study
2007
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
2015
Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment
2011
Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma
2008
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
2014
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial
2008
Onco‐miR‐155 targets SHIP1 to promote TNFα‐dependent growth of B cell lymphomas
2009
Head and neck squamous cell carcinoma
2020 Standout
Cancer statistics, 2024
2024 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Waldenström Macroglobulinemia: 2012 update on diagnosis, risk stratification, and management
2012
Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
2014 Standout
Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma
2016
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
2009
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
1998 Standout
Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis
2007
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Circulating cell-free and Epstein–Barr virus DNA in pediatric B-non-Hodgkin lymphomas
2010
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2014 Standout
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
2013 Standout
Antibodies in oncology
2011
Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation
1995
Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate
2008
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
2021
3D Slicer as an image computing platform for the Quantitative Imaging Network
2012 Standout
Utility of positron emission tomography scans in mantle cell lymphoma
2011
Antibody therapy of cancer
2012 Standout
Factors Considered Important at the End of Life by Patients, Family, Physicians, and Other Care Providers
2000 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients
2012
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings
2008
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group
2010
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
2012 Standout
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2012
Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy
2006
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
2009 StandoutNobel
Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2
2014
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells
2010 Standout
Updated clinical practice guidelines for the prevention and treatment of mucositis
2007
FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer
2006
Monoclonal Antibodies in the Treatment of Non-Hodgkin???s Lymphoma
2007
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
Circulating nucleic acids (CNAs) and cancer—A survey
2006
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Overview of early response assessment in lymphoma with FDG-PET
2007
Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma
2003
Pediatric Hodgkin Lymphoma: Maximizing Efficacy and Minimizing Toxicity
2007
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
2009 Standout
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
2009
Rituximab-Associated Infections
2010
Monoclonal antibodies in myeloma.
2015
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.
2009
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
1999 StandoutScience
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
2011
Role of Functional Imaging in the Management of Lymphoma
2011
Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases
2013
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
2009
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients
2006
The therapeutic use of rituximab in non‐Hodgkin's lymphoma
2006
Revised Response Criteria for Malignant Lymphoma
2007 Standout
The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
2007 Standout
The Tumor Lysis Syndrome
2011 Standout
A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation
2008
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma
2008
Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management
2013
Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
2012
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy?
2015
Clinical management of dying patients.
1995
Proteasome Inhibition Alleviates SNARE-Dependent Neurodegeneration
2012 StandoutNobel
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
2014
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
2008
Treatment of the Newly Diagnosed Adult with De Noyo Acute Myeloid Leukemia
1993
Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non–Small-Cell Lung Cancer
2003
PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement
2013
Cancer treatment and survivorship statistics, 2019
2019 Standout
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD
2014
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
2013 Standout
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Standardization of sample collection, isolation and analysis methods in extracellular vesicle research
2013 Standout
Multiple Myeloma
2011 Standout
Utility of FDG-PET scanning in lymphoma by WHO classification
2003
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
2009
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma
2009
18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.
2005
Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin’s Lymphoma Patients Treated with Rituximab-Containing Regimens
2011
A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone
2007
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
1993
Cancer treatment and survivorship statistics, 2014
2014 Standout
Works of Max Wolf being referenced
BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study
2010
Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma
2006
A randomised trial of dexamethasone, lorazepam and prochlorperazine for emesis in patients receiving chemotherapy
1992
Etoposide in leukemia
1991
[18F]Fluorodeoxyglucose Positron Emission Tomography Scanning for Staging, Response Assessment, and Disease Surveillance in Patients with Mantle Cell Lymphoma
2008
A new model for predicting infectious complications during fludarabine‐based combination chemotherapy among patients with indolent lymphoid malignancies
2004
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
2008
Early therapeutic response assessment by18FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure
2007
A Phase Ib Clinical Trial of PV701, a Milk-Derived Protein Extract, for the Prevention and Treatment of Oral Mucositis in Patients Undergoing High-Dose BEAM Chemotherapy
2005
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma
2002
Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia
2010
A randomised double-blind study of high-dose intravenous prochlorperazine versus high-dose metoclopramide as antiemetics for cancer chemotherapy
1992
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non‐hodgkin lymphoma
2006
Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma
1997
Comparison of COBE� Spectra? software version 4.7 PBSC and version 6.0 auto PBSC? program
1999
The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement
2006
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
2010
Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.
2007
Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma
2006
Chimeric Anti-CD20 Monoclonal Antibody (Rituximab; Mabtheraa) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma : A Phase III Randomized Intergroup Clinical Trial.
2004
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
2006
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia
2019
Chimeric Anti-CD20 Monoclonal Antibody (Rituximab;Mabthera) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma: Final Analysis of a Phase III Randomized Intergroup Clinical Trial.
2005
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
2008